Prescription Drug Pipeline
Chronic Pain – Prescription Drugs
Existing data indicates that palmitoylethanolamide may have both a solo mechanism of action and a “potentiating” or “synergistic” effect when administered concomitantly with certain target prescription drugs such as morphine, oxycodone, hydrocodone, pregabalin, gabapentin, and tramadol. Prismic expects to be able to demonstrate the concept that concomitant administration of palmitoylethanolamide with these target drugs results in achieving the desired therapeutic effect at lower doses of the target drugs, and the potential consequent avoidance or lessening of adverse events or side effects, including extending the period before which tolerance to the target drugs occur. For example, in a recent animal study where palmitoylethanolamide was taken concomitantly with morphine the period before which tolerance to the morphine occurred was doubled.
© Copyright by Prismic Pharmaceuticals, Inc.®, 2011-2017. All rights reserved. NEUREPA® by Prismic Pharmaceuticals, Inc®.
Prismic Pharmaceuticals, Inc.
Attn: Zachary Dutton
95 Prescott Street
Worcester, Massachusetts 01605